Recent Updates
Recently added Catalysts
NBIX Positive Sentiment Score: 60/100

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and...

Key Takeaway: Neurocrine Biosciences, Inc. has announced a scheduled conference call and webcast for discussing its third quarter 2024 financial results. This event is set for October 30, 2024, at 5:00 a.m. PT. A press release will precede the call, and a replay will be made available shortly after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of third quarter 2024 financial results indicates ongoing operations.
  • Conference call offers opportunity for investor engagement and transparency.
  • Neurocrine has a diverse portfolio of FDA-approved treatments and clinical pipelines.

Full Press Release Details

Conference Call and Webcast Scheduled for Wednesday, October 30
SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on October 30, 2024 .
The schedule for the press release and conference call / webcast is as follows:
• Q3 2024 Press Release: October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET
• Q3 2024 Conference Call: October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
• Domestic Dial-In Number: 800-225-9448
• International Dial-In Number: 203-518-9708
• Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (Formerly Twitter) and Facebook . (* in collaboration with AbbVie )
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
SOURCE Neurocrine Biosciences, Inc.

21 %

Frequently Asked Questions

When is Neurocrine Biosciences' Q3 2024 conference call?

The Q3 2024 conference call is scheduled for October 30, 2024, at 5:00 a.m. PT.

How can I access the Neurocrine Biosciences webcast?

The webcast can be accessed on Neurocrine's website under Investors at www.neurocrine.com.

What is the conference ID for the call?

The conference ID for the call is NBIX.

What time will the press release be available?

The Q3 2024 press release will be available on October 30, 2024, at 4:00 a.m. PT.

What numbers can I dial for the conference call?

Domestic callers can dial 800-225-9448, while international callers should use 203-518-9708.

Last updated: Oct 9, 2024